Cargando…
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
With programmed death 1/ligand 1 (PD-1/PD-L1) as the cornerstone, anti-PD antibodies have pioneered revolutionary immunotherapies for malignancies. But most patients struggled to respond to anti-PD owing to primary or acquired resistance or even hyperprogression, pointing to more efforts needed to e...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157498/ https://www.ncbi.nlm.nih.gov/pubmed/35663968 http://dx.doi.org/10.3389/fimmu.2022.910704 |